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Abstract

Objective Proton pump inhibitors (PPIs) are widely used,
and their use is associated with increased risk of adverse
events. However, whether PPI use is associated with
excess risk of death is unknown. We aimed to examine
the association between PPI use and risk of all-cause
mortality.
Design Longitudinal observational cohort study.
Setting US Department of Veterans Affairs.
Participants Primary cohort of new users of PPI
or histamine H2 receptor antagonists (H2 blockers)
(n=349 312); additional cohorts included PPI versus no PPI
(n=3 288 092) and PPI versus no PPI and no H2 blockers
(n=2 887 030).
Main outcome measures Risk of death.
Results Over a median follow-up of 5.71 years (IQR
5.11–6.37), PPI use was associated with increased risk of
death compared with H2 blockers use (HR 1.25, CI 1.23
to 1.28). Risk of death associated with PPI use was higher
in analyses adjusted for high-dimensional propensity
score (HR 1.16, CI 1.13 to 1.18), in two-stage residual
inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1
time-dependent propensity score-matched cohort (HR
1.34, CI 1.29 to 1.39). The risk of death was increased
when considering PPI use versus no PPI (HR 1.15, CI 1.14
to 1.15), and PPI use versus no PPI and no H2 blockers
(HR 1.23, CI 1.22 to 1.24). Risk of death associated
with PPI use was increased among participants without
gastrointestinal conditions: PPI versus H2 blockers (HR
1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19,
CI 1.18 to 1.20) and PPI use versus no PPI and no H2
blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users,
there was a graded association between the duration of
exposure and the risk of death.
Conclusions The results suggest excess risk of death
among PPI users; risk is also increased among those
without gastrointestinal conditions and with prolonged
duration of use. Limiting PPI use and duration to instances
where it is medically indicated may be warranted.

Introduction
Proton pump inhibitors (PPI) are widely
prescribed and are also available for sale
over the counter without prescription in
several countries.1 2 Several observational
studies suggest that PPI use is associated with

Strengths and limitations of this study
►► National large-scale data from a network of

integrated health systems.
►► Employed a new user design and developed

a number of analytical approaches where we
consistently found a significant association between
PPI exposure and risk of death.
►► Cohort included mostly older white male US
veterans, which may limit the generalisability.
►► Did not include information on the cause of death.

increased risk of a number of adverse health
outcomes.1 A number of studies have shown
that PPI use is associated with significant
risk of acute interstitial nephritis.3–5 Recent
studies established an association between
exposure to PPI and risk of chronic kidney
disease (CKD), kidney disease progression
and end-stage renal disease.2 6 7 Results from
a large prospective observational German
cohort suggest that patients receiving PPI had
a higher risk of incident dementia.8 Several
reports highlighted a rare but potentially
fatal risk of hypomagnesemia among users
of PPI.9–11 PPI use has been associated with
increased risk of both incident and recurrent Clostridium difficile infections.12 Several
observational analyses have shown that PPI
use was also associated with increased risk
of osteoporotic fractures, including hip and
spine fractures.13 14 Less convincing—and to
some extent inconsistent—evidence suggests
a relationship between PPI use and risks of
community-acquired pneumonia and cardiovascular events.15–17 Emerging—and far from
conclusive—in vitro evidence suggests that
PPI results in inhibition of lysosomal acidification and impairment of proteostasis,
leading to increased oxidative stress, endothelial dysfunction, telomere shortening and
accelerated senescence in human endothelial cells.18 The experimental work provides a
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putative mechanistic link to explain some of the adverse
events associated with PPI use.18
The adverse outcomes associated with PPI use are
serious, and each is independently associated with higher
risk of mortality. Evidence from several small cohort
studies of older adults who were recently discharged from
the hospital or institutionalised in long-term care facilities suggests inconsistently that PPI use may be associated
with increased risk of 1 year mortality.19–22 Whether PPI
use is associated with excess risk of death is not known
and has not been examined in large epidemiological
studies spanning a sufficiently long duration of follow-up.
We hypothesised that owing to the consistently observed
associations between PPI use and risk of adverse health
outcomes, PPI use is associated with excess risk of death,
and that the risk of death would be more pronounced with
increased duration of use. We therefore used the Department of Veterans Affairs national databases to build a
longitudinal cohort of incident users of acid suppression
therapy, including PPI and histamine H2 receptor antagonists (H2 blockers), to examine the association between
PPI use and risk of all-cause mortality and to determine
whether risk of death is increased with prolonged duration of use.
Methods
Cohort participants
Primary cohort
Using administrative data from the US Department of
Veterans Affairs, we identified patients who received
an outpatient H2 blockers or PPI prescription between
1 October 2006 and 30 September 2008 (n=1 762 908).
In order to select new users of acid suppression therapy
(incident user design), we excluded 1 356 948 patients
who received any outpatient H2 blockers or PPI prescriptions between 1 October 1998 and 30 September 2006. To
account for patients’ kidney function, only patients with
at least one outpatient serum creatinine value before the
first acid suppression therapy prescription were selected
in the cohort, yielding an analytic cohort of 349 312
patients. Patients whose first acid suppression therapy was
PPI (n=275 977) were considered to be in the PPI group
during follow-up. Patients who received H2 blockers as
their first acid suppression therapy (n=73 335) served
as the reference group before they received any PPI
prescription (see online supplementary figure 1). Within
the reference group, those who received a PPI prescription later (n=33 136) were considered to be in the PPI
group from the date of their first PPI prescription until
the end of follow-up.23 Time zero (T0) for primary cohort
was defined as the first acid suppression therapy prescription date.
Secondary cohorts
We additionally built two secondary cohorts to examine
the association of PPI use and risk of death in (a) PPI
versus no PPI users and (b) PPI versus non-users of acid
2

suppression therapy. Patients with no PPI prescription
between 1 October 1998 and 30 September 2006, and
with at least one outpatient eGFR value before 1 October
2006, were selected to evaluate the risk of death associated
with PPI use versus no PPI use (n=3 288 092) (see online
supplementary figure 2a). Patients with no PPI prescription between 1 October 1998 and 30 September 2006,
with no H2 blockers before the first PPI prescription and
at least one outpatient eGFR value before 1 October 2006,
were selected to evaluate the risk of death associated with
PPI use versus no acid suppression therapy (n=2 887 030)
(se online supplementary figure 2b). T0 for secondary
cohorts was defined as 1 October 2006.
Patients in both primary and secondary cohorts were
followed until 30 September 2013 or death. The study
was approved by the Institutional Review Board of the VA
Saint Louis Health Care System, Saint Louis, Missouri.
Data sources
We used the Department of Veterans Affairs databases,
including inpatient and outpatient medical SAS data
sets (that include utilisation of data related to all inpatient and outpatient encounters within the VA system),
to ascertain detailed patient demographic characteristics and comorbidity information based on inpatient
and outpatient encounters.2 24 The VA Managerial Cost
Accounting System Laboratory Results (a comprehensive database that includes VA-wide results for selected
laboratory tests obtained in the clinical setting) provided
information on outpatient and inpatient laboratory
results. The VA Corporate Data Warehouse Production
Outpatient Pharmacy domain provided information on
outpatient prescriptions. The VA Vital Status and Beneficiary Identification Records Locator Subsystem files
provided demographic characteristics and death.
Primary predictor variable
PPI use was the primary predictor. Once cohort participants received PPI prescription, they were considered with
the effect of PPI until the end of follow-up. Medications
that contain esomeprazole, lansoprazole, omeprazole,
pantoprazole or rabeprazole were counted as PPI. Medications including ranitidine, cimetidine and famotidine
were counted as H2 blockers.
Outcome
The primary outcome in survival analyses was time to
death. Death information is routinely collected by the
Veterans Benefit Administration for all United States
Veterans.
Covariates
Covariates included age, race, gender, eGFR, number of
outpatient serum creatinine measurements, number of
hospitalisations, diabetes mellitus, hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular
disease, chronic lung disease, cancer, hepatitis C, HIV,
dementia and diseases associated with acid suppression
Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735
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therapy use such as gastro-oesophageal reflux disease
(GERD), upper gastrointestinal (GI) tract bleeding, ulcer
disease, Helicobacter pylori infection, Barrett’s oesophagus,
achalasia, stricture and oesophageal adenocarcinoma.25–28
eGFR was calculated using the abbreviated four-variable
CKD epidemiology collaboration equation based on
age, sex, race and outpatient serum creatinine.29 Race/
ethnicity was categorised as white, black or other (Latino,
Asian, Native American or other racial/ethnic minority
groups). Comorbidities except for hepatitis C and HIV
were assigned on the basis of relevant ICD-9-CM (the
International Classification of Diseases, Ninth Revision,
Clinical Modification) diagnostic and procedure codes
and Current Procedural Terminology (CPT) codes in the
VA Medical SAS data sets.2 30–33 Hepatitis C and HIV were
assigned based on laboratory results.
Baseline covariates were ascertained from 1 October
1998 till T0. All covariates except for age, race and gender
covariates values were treated as time-varying covariates
where they were additionally assessed until the date of the
first PPI prescription in those patients who did not have
PPI prescription at T0. Any comorbidity occurring during
the assessment period was considered present during the
remaining follow-up. eGFR was the outpatient eGFR value
within and most proximate to the end of the assessment
period. Number of outpatient serum creatinine measurements and number of hospitalisations were accumulated
during the assessment period.
Statistical analysis
Means, SD and t-tests are presented for normally distributed continuous variables; medians, interquartile ranges
and Wilcoxon-Mann-Whitney tests are presented for
non-normally distributed continuous variables; and
counts, percentages and χ2 tests are presented for categorical variables. Incident rates per 100 person-years were
computed for death, and CIs were estimated based on the
normal distribution. The Simon and Makuch method for
survival curves was used for time-dependent covariates.34
Cox regression models with time-dependent covariates
were used in the assessment of the association between
PPI exposure and risk of death where patients could
switch from H2 blockers to PPI in the models. In order to
account for potential delayed effect of PPI, patients were
considered to have the effect of PPI from the first PPI
prescription till the end of follow-up. In addition, time-dependent Cox models were conducted in subgroups where
patients had no GI conditions and where patients had
no GI conditions except for GERD and in the secondary
cohorts.
Because exposure in this observational cohort is time
dependent, we undertook 1:1 propensity score matching
for the primary cohort where time-dependent propensity scores were calculated based on time-dependent
Cox regression with all covariates35 (details are provided
in online supplementary methods). After matching, all
covariates except for age had an absolute standardised
difference of less than 0.1, which indicated that all
Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735

covariates except age were well balanced. Age had a
standardised difference equal to 0.13. Doubly robust estimation was applied after matching, where all covariates
were additionally controlled for in the model to obtain an
unbiased effect estimator.36
In order to optimise control of confounding, we
additionally built high-dimensional propensity score-adjusted survival models following the multistep algorithm
described by Schneeweiss et al37 (details are provided
in online supplementary methods). We also applied a
two-stage residual inclusion estimation based on instrumental variable approach (see online supplementary
methods)38
In addition, we evaluated the association between duration of PPI prescription and risk of death among new
users of PPI. Duration was defined in cumulative days of
use and categorised as ≤30, 31–90, 91–180, 181–360 and
361–720, where ≤30 days was considered as the reference group. To avoid immortal time bias (by definition,
cohort participants must be alive to receive prescription hence introducing a bias commonly referred to as
immortal time bias), time of cohort entry was defined
as the date of last PPI prescription plus days’ supply.39 40
In order to ensure sufficient length of follow-up time
following T0, we excluded cohort participants with
cumulative duration of exposure exceeding 720 days
(because of limited overall cohort timeline, and because
T0 starts at the end of last prescription, those with long
exposure will necessarily have limited follow-up time).
In regression analyses, a 95% CI of an HR that does not
include unity was considered statistically significant. All
analyses were performed using SAS Enterprise Guide
version 7.1.
Sensitivity analyses
In order to further evaluate the consistency and robustness of study findings, we examined the observed
associations in a less contemporary cohort (dating back
to an era where PPI prescription and use were far less
frequent) of patients without acid suppression therapy
prescriptions between 1 October 1998 and 30 September
2000 (washout period) and with acid suppression therapy
prescription between 1 October 2000 and 30 September
2002 and at least one outpatient serum creatinine value
before that. Patients in this cohort were followed till
30 September 2007 or death. To examine the impact
of potential residual confounding on study results, we
conducted additional sensitivity analyses as described by
Schneeweiss41: (a) we used the rule-out approach to identify the strength of the residual confounding that could
fully explain the association observed in primary analyses,
and (b) we applied an external adjustment approach
using external information (prevalence and risk estimates from published literature) to evaluate potential net
confounding bias due to unmeasured confounders.2 41–44
Methods are described elegantly by Schneeweiss.41 In
addition, to remove death events that were less likely to be
related to PPI exposure, we excluded cohort participants
3
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who died within 90 days after the first PPI or H2 blocker
prescription.
We conducted analyses based on a three-level classification of exposure, where patient’s status at time t could be
current use (using PPI or finished last PPI prescription
within 90 days before t), past use (used PPI after T0 but
finished more than 90 days before t) and never use. We
conducted additional sensitivity analyses, which included
haemoglobin as a covariate in cohort participants with
available data. We also undertook analyses that stratified
the cohort based on cardiovascular disease, history of
pneumonia, CKD (eGFR <60 and ≥60 mL/min/1.73 m2)
or age (<65 and ≥65 years old) at T0. Finally, and in order
to ascertain the specificity of the findings, we examined
the association between PPI exposure and the risk of a
motor vehicle accident as a tracer outcome where a priori
knowledge suggests an association is not likely to exist.
Patient involvement
No patients were involved in developing the hypothesis,
the specific aims or the research questions, nor were
they involved in developing plans for design or implementation of the study. No patients were involved in the
interpretation of study results or write up of the manuscript. There are no plans to disseminate the results of
the research to study participants or the relevant patient
community.
Results
The demographic and health characteristics of the overall
primary cohort of new users of acid suppression therapy
(n=349 312), by type of acid suppressant drug at time
of cohort entry (H2 blockers n=73 335; PPI n=275 977),
and those who were ever exposed to PPI (n=309 113) are
provided in table 1. There were significant baseline differences in that cohort participants who were treated with
PPI were older and were more likely to have comorbid
conditions, including diabetes, hypertension, cardiovascular disease and hyperlipidaemia. Cohort participants
treated with PPI were also more likely to have upper GI
tract bleeding, ulcer disease, H. pylori infection, Barrett’s
oesophagus, achalasia, stricture and oesophageal adenocarcinoma (table 1). Survival curves for PPI and H2
blockers are presented in figure 1.
Association between PPI use and risk of death
Among new users of acid suppression therapy (n=349 312),
and over a median follow-up of 5.71 years (IQR 5.11–
6.37), where exposure was treated as a time-dependent
covariate, PPI use was associated with increased risk of
death compared with H2 blockers use (HR 1.25, CI 1.23
to 1.28) (table 2). Among new users of acid suppression
therapy (n=3 49 312), in high-dimensional propensity
score-adjusted models, new PPI users had increased risk
of death compared with new users of H2 blockers (HR
1.16, CI 1.13 to 1.18); based on two-stage residual inclusion estimation, risk of death was higher in new PPI users
when compared with new users of H2 blockers (HR 1.21,
4

CI 1.16 to 1.26). In a 1:1 time-dependent propensity scorematched cohort of new users of PPI and H2 blockers
(n=1 46 670), PPI users had significantly increased risk of
death (HR 1.34, CI 1.29 to 1.39).
We examined the relationship of PPI and risk of death
in secondary cohorts (as described in the Methods
section) where we considered risk associated with PPI
use versus no known exposure to PPI (no PPI use ±H2
blockers use) (n=3 288 092); the results suggest that PPI
use was associated with increased risk of death (HR 1.15,
CI 1.14 to 1.15) (table 2). Assessment of risk of death associated with PPI use versus no known exposure to any acid
suppression therapy (no PPI use and no H2 blockers use)
(n=2 887 070) suggests increased risk of death with PPI
use (HR 1.23, CI 1.22 to 1.24).
Association between PPI use and risk of death in those
without GI conditions
We then analysed the association between PPI use and risk
of death in cohort where we excluded participants with
documented medical conditions generally considered
as indications for treatment with PPI, including GERD,
upper GI tract bleeding, ulcer disease, H. pylori infection,
Barrett’s oesophagus, achalasia, stricture and oesophageal adenocarcinoma. The intent of this analysis was to
examine the putative association of PPI use and risk of
death in a lower risk cohort. Examination of risk of death
associated with use of acid suppression therapy (PPI vs H2
blockers) suggests that risk of death was increased with
PPI use (HR 1.24, CI 1.21 to 1.27) (table 2). Examination of the risk of death associated with PPI use versus no
known exposure to PPI (no PPI use ±H2 blockers use)
suggests a higher risk of death associated with PPI use
(HR 1.19, CI 1.18 to 1.20). Results were consistent where
we examined risk of death associated with PPI use versus
no known exposure to any acid suppression therapy (no
PPI use and no H2 blockers use) (HR 1.22, CI 1.21 to
1.23). Risk of death associated with PPI use in cohort
participants without GI conditions but included participants with GERD yielded consistent results (PPI vs H2
blockers (HR 1.24, CI 1.21 to 1.27); PPI vs no PPI (HR
1.14, CI 1.13 to 1.14); PPI vs no PPI and no H2 blockers
(HR 1.22, CI 1.21 to 1.22)) (table 2).
Duration of exposure and excess risk of death
We examined the association between duration of PPI
exposure and risk of death among new users of PPI
(n=166 098). Compared with those exposed for ≤30 days,
there was a graded association between duration of exposure and risk of death among those exposed for 31–90,
91–180, 181–360 and 361–720 days (table 3, figure 2).
Sensitivity analyses
We tested the robustness of study results in sensitivity
analyses where we built a less contemporary cohort as
described in the Methods section; demographic and
health characteristics of this cohort are provided in online
supplementary table 1. Where exposure was treated as
Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735

14 596 (4.18)

Other (%)
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2225 (3.03)
17 436 (23.78)

70 281 (20.12)
11 439 (3.27)
98 137 (28.09)
1858 (0.53)
16 421 (4.70)
200 397 (57.37)
5034 (1.44)
114 (0.03)
49 666 (14.22)
100 980 (28.91)
9310 (2.67)
25 626 (7.34)
3078 (0.88)
2324 (0.67)
151 (0.04)
1992 (0.57)
213 (0.06)

Chronic lung disease (%)

Peripheral artery disease (%)

Cardiovascular disease (%)

Cerebrovascular disease (%)

Dementia (%)

Hyperlipidaemia (%)

Hepatitis C (%)

HIV (%)

Cancer (%)

GERD (%)

Upper GI tract bleeding (%)

Ulcer disease (%)

Helicobacter pylori infection (%)

Barrett’s oesophagus (%)

Achalasia (%)

Stricture (%)
Oesophageal adenocarcinoma (%)

132 (0.18)
17 (0.02)

10 (0.01)

89 (0.12)

141 (0.19)

3564 (4.86)

926 (1.26)

20 562 (28.04)

9123 (12.44)

38 (0.05)

1184 (1.61)

39 818 (54.30)

3115 (4.25)

372 (0.51)

13 849 (18.88)

44 502 (60.68)

225 899 (64.67)

Hypertension (%)

16 758 (22.85)

90 273 (25.84)

5587 (7.62)

67 748 (92.38)

3576 (4.88)

13 229 (18.04)

56 530 (77.08)

0.52 (1.45)

6.67 (7.39)

79.64 (21.96)

73 335
58.48 (15.13)

Diabetes mellitus (%)

22 653 (6.49)

59 243 (16.96)

Black (%)

Female (%)

275 473 (78.86)

White (%)

Race

326 659 (93.51)

0.51 (1.39)

Number of hospitalisations (SD)

Male (%)

6.85 (7.55)

Sex

76.89 (22.66)

eGFR in mL/min/1.73 m (SD)

2

349 312
61.00 (14.92)

Number of outpatient serum creatinine
measurements (SD)

N
Age (SD)

Overall cohort

New users of H2
blockers at time of
cohort entry

1860 (0.67)
196 (0.07)

141 (0.05)

2235 (0.81)

2937 (1.06)

22 062 (7.99)

8384 (3.04)

80 418 (29.14)

40 543 (14.69)

76 (0.03)

3850 (1.40)

160 579 (58.19)

13 306 (4.82)

1486 (0.54)

80 701 (29.24)

9214 (3.34)

56 432 (20.45)

181 397 (65.73)

73 515 (26.64)

17 066 (6.18)

258 911 (93.82)

11 020 (3.99)

46 014 (16.67)

218 943 (79.33)

0.51 (1.37)

6.89 (7.59)

76.16 (22.79)

275 977
61.67 (14.79)

New users of PPI at time
of cohort entry

2051 (0.66)
213 (0.07)

154 (0.05)

2382 (0.77)

3239 (1.05)

24 864 (8.04)

9098 (2.94)

94 517 (30.58)

45 633 (14.76)

113 (0.04)

4444 (1.44)

181 524 (58.72)

15 384 (4.98)

1719 (0.56)

89 878 (29.08)

10 680 (3.46)

64 777 (20.96)

203 700 (65.90)

82 168 (26.58)

19 880 (6.43)

289 233 (93.57)

12 676 (4.10)

52 207 (16.89)

244 230 (79.01)

0.56 (1.49)

7.27 (8.00)

76.60 (22.79)

309 113
61.37 (14.77)

Ever exposed to PPI*

<0.001
<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.001

<0.001

<0.001

<0.001

0.30

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.014

<0.001

<0.001

<0.001

Continued

p Value†

Table 1 Baseline demographic and health characteristics of overall primary cohort of new users of acid suppression therapy, by type of acid suppressant at the time of
cohort entry, and those who were ever exposed to PPI
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Figure 1 Survival curves for PPI and H2 blockers. PPI,
proton pump inhibitor.
*Includes patients exposed to PPI at T0 (n=275 977) and during follow-up (n=33 136). Variables were measured at time of PPI exposure.
†p value for difference between exposed to H2 at T0 and exposed to PPI at T0.
‡From T0 to the first occurrence of death or 30 September 2013.
§Outcome measured from T0 to the first occurrence of exposure PPI, death or 30 September 2013.
¶Days of having PPI or H2 blockers.
eGFR, estimated glomerular filtration rate; GERD, gastro-oesophageal reflux disease; PPI, proton pump inhibitor.

<0.001
<0.001
72 445 (23.44)
4.67
(4.64–4.71)
67 450 (24.44)
4.74
(4.70–4.77)
81 463 (23.32)
4.47
(4.44–4.50)
Death (%)
Incident death in 100 person-years (95% CI)

9018 (12.30)§
3.32
(3.25–3.39)§

<0.001
450
(120–1266)
450
(120–1299)
442
(199–1272)¶
Days of having related prescription during
follow-up (IQR)

120
(60–400)§

<0.001
5.59
(4.82–6.28)
5.67
(5.09–6.34)
5.71
(5.11–6.37)

4.38
(1.16–5.92)§

p Value†

Years of follow-up (IQR)

Table 1

Continued

‡

Overall cohort

New users of H2
blockers at time of
cohort entry

New users of PPI at time
of cohort entry

Ever exposed to PPI*

Open Access

time dependent, PPI use was associated with increased
risk of death compared with H2 blockers use (HR 1.17,
CI 1.15 to 1.19). In a 1:1 time-dependent propensity
score-matched cohort of PPI and H2 blockers, PPI users
had significantly increased risk of death HR 1.21 (CI 1.19
to 1.24). Furthermore, we also observed a graded association between cumulative duration of exposure to PPI
and risk of death (see online supplementary table 2 and
online supplementary figure 3).
To examine the potential impact of residual
confounding on study results, we used rule-out and
external adjustment approaches as described by Schneeweiss.41 Using the rule-out approach, we characterised
a set of parameters (OR for relationship of PPI and
confounder and HR for relationship of confounder
and death) with sufficient strength to fully explain the
association observed in primary analyses (see online
supplementary figure 4). For example, if the confounder
was two times as likely among PPI users (OR=2), and the
HR of death associated with the uncontrolled confounder
exceeded 4.0, then the uncontrolled confounder would
fully explain the observed association between PPI and
death (see online supplementary figure 4). Given that
our analyses accounted for most known strong independent risk factors of death and employed an active
comparator group, to cancel the results, any uncontrolled
confounder of the required prevalence (OR 2 or more in
the example above) and strength (HR 4 or more in the
example above) would also have to be independent of the
confounders already adjusted for and is unlikely to exist;
thus, the results cannot be fully explained by this putative
uncontrolled confounder.
External adjustment to estimate the impact of three
unmeasured confounders, including obesity, smoking
and use of therapeutics including anticoagulants, antiplatelet agents and non-steroidal anti-inflammatory
drugs, shows a net confounding bias of 9.66% (see online
supplementary figure 5). The total bias could move a null
association between PPI and death from HR 1.00 to HR
1.10 (reflecting the net positive bias of 9.66% rounded up
Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735
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Table 2 Association between PPI use and risk of death
Association between PPI and death
PPI use vs H2 blockers use
(n=3 49 312)
High-dimensional propensity score-adjusted
model of new users of PPI vs H2 blockers
(n=3 49 312)

Reference

PPI use

Incident rate (95% CI)
Unadjusted HR (95% CI)

3.32 (3.25 to 3.39)
1

4.67 (4.64 to 4.71)
1.46 (1.43 to 1.49)

Adjusted HR (95% CI)

1

1.25 (1.23 to 1.28)

Incident rate (95% CI)

3.32 (3.25 to 3.39)

4.74 (4.70 to 4.77)

HR (95% CI)

1

1.16 (1.13 to 1.18)

3.32 (3.25 to 3.39)

4.74 (4.70 to 4.77)

1

1.21 (1.16 to 1.26)

Two-stage residual inclusion estimation model Incident rate (95% CI)
of new users of PPI vs H2 blockers
HR (95% CI)
(n=3 18 960)
Time-dependent propensity score-matched
PPI vs H2 blockers
(n=1 46 670)

Incident rate (95% CI)

3.32 (3.25 to 3.39)

4.37 (4.30 to 4.44)

Unadjusted HR (95% CI)

1

1.38 (1.34 to 1.42)

Adjusted HR (95% CI)

1

1.34 (1.29 to 1.39)

PPI use vs no PPI
(n=3 288 092)

Incident rate (95% CI)

3.64 (3.63 to 3.65)

5.50 (5.47 to 5.53)

Unadjusted HR (95% CI)

1

1.47 (1.46 to 1.48)

Adjusted HR (95% CI)

1

1.15 (1.14 to 1.15)

PPI use vs no PPI or H2 blockers
(n=2 886 879)

Incident rate (95% CI)

3.47 (3.46 to 3.48)

5.50 (5.47 to 5.53)

Unadjusted HR (95% CI)

1

1.53 (1.52 to 1.54)

Adjusted HR (95% CI)

1

1.23 (1.22 to 1.24)

PPI vs H2 blockers in a cohort without GI
conditions
(n=2 14 521)

Incident rate (95% CI)

3.80 (3.71 to 3.89)

5.39 (5.34 to 5.44)

Unadjusted HR (95% CI)

1

1.47 (1.43 to 1.51)

Adjusted HR (95% CI)

1

1.24 (1.21 to 1.27)

3.54 (3.53 to 3.55)

5.89 (5.86 to 5.93)

PPI vs no PPI in a cohort without GI conditions Incident rate (95% CI)
(n=2 790 697)
Unadjusted HR (95% CI)
PPI vs no PPI or H2 blockers in a cohort
without GI conditions
(n=2 543 480)
PPI vs H2 blockers in a cohort without GI
conditions except for GERD
(n=311 115)

1

1.62 (1.61 to 1.63)

Adjusted HR (95% CI)

1

1.19 (1.18 to 1.20)

Incident rate (95% CI)

3.45 (3.44 to 3.46)

5.89 (5.86 to 5.93)

Unadjusted HR (95% CI)

1

1.65 (1.64 to 1.67)

Adjusted HR (95% CI)

1

1.22 (1.21 to 1.23)

Incident rate (95% CI)

3.30 (3.23 to 3.37)

4.51 (4.47 to 4.54)

Unadjusted HR (95% CI)

1

1.42 (1.38 to 1.45)

Adjusted HR (95% CI)

1

1.24 (1.21 to 1.27)

3.59
(3.58 to 3.60)

5.36 (5.34 to 5.39)

1

1.45 (1.44 to 1.46)

Adjusted HR (95% CI)

1

1.14 (1.13 to 1.14)

Incident rate (95% CI)

3.44 (3.44 to 3.45)

5.36 (5.34 to 5.39)

Unadjusted HR (95% CI)
Adjusted HR (95% CI)

1
1

1.50 (1.49 to 1.51)
1.22 (1.21 to 1.22)

PPI vs no PPI in a cohort without GI conditions Incident rate (95% CI)
except for GERD
(n=3 132 126)
Unadjusted HR (95% CI)
PPI vs no PPI or H2 blockers in a cohort
without GI conditions except for GERD
(n=2 678 478)

Incident rate as incident death in 100 person-years.
All models except time-dependent propensity score-matched and high-dimensional propensity score-adjusted models were time-dependent
models. Effect of PPI was treated as time dependent and was defined as once patients used PPI, they were in PPI group during the remaining
follow-up.
Adjusted model controlling for eGFR, age, race, gender, number of serum creatinine measurements, number of hospitalisations, diabetes
mellitus, hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C,
HIV, dementia, cancer, GERD, upper GI tract bleeding, ulcer disease, H. pylori infection, Barrett’s oesophagus, achalasia, stricture and
oesophageal adenocarcinoma, unless used in analysis inclusion criteria.
GI conditions include upper GI tract bleeding, ulcer disease, H. pylori infection, Barrett’s oesophagus, achalasia, stricture and oesophageal
adenocarcinoma.
GERD, gastro-oesophageal reflux disease; GI, gastrointestinal; PPI, proton pump inhibitor.
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Table 3 Duration of exposure to PPI and risk of death among new users of PPI (n=1 66 098)
Duration (days)

≤30

31–90

91–180

181–360

361–720

N
(%)
HR (95% CI)

24 748 (14.90)

39 345 (23.69)

29 334 (17.66)

33 907 (20.41)

38 764 (23.34)

1

1.05 (1.02 to 1.08)

1.17 (1.13 to 1.20)

1.31 (1.27 to 1.34)

1.51 (1.47 to 1.56)

Within people exposed to PPI between 1 and 720 days.
Model controls for eGFR, age, race, gender, number of serum creatinine measurements, number of hospitalisations, diabetes mellitus,
hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia,
cancer, GERD, upper GI tract bleeding, ulcer disease, Helicobacter pylori infection, Barrett’s oesophagus, achalasia, stricture and
oesophageal adenocarcinoma.
Time zero defined as date when the patient's last PPI prescription ends.
GERD, gastro-oesophageal reflux disease; GI, gastrointestinal; PPI, proton pump inhibitor.

to 10.0%). The association we observed between PPI and
death was 1.25>1.10, which cannot be fully due to bias of
unmeasured confounding.
In analyses where time-dependent exposure was classified as current use (within 90 days), past use (use prior
to 90 days) and never use of PPI, compared with use of
H2 blockers and never use of PPI (the reference group),
current use of PPI and past use of PPI were associated
with increased in risk of death (HR 1.23, CI 1.21 to 1.26,
and HR 1.53, CI 1.50 to 1.57, respectively).
The association between PPI and death remained significant after excluding cohort participants who died within
90 days after the first PPI or H2 blocker prescription
(HR 1.23, CI 1.20 to 1.26), or additionally controlling for
haemoglobin levels (HR 1.25, CI 1.23 to 1.28). In models
stratified for the presence of cardiovascular disease,
history of pneumonia, CKD and age at T0, there was
increased risk of death associated with PPI use in those
with and without cardiovascular disease (HR 1.19, CI 1.15
to 1.23, and HR 1.30, CI 1.27 to 1.34, respectively), with
and without history of pneumonia (HR 1.39, CI 1.32 to
1.45, and HR 1.21, CI 1.18 to 1.24, respectively), with and
without CKD (HR 1.18, CI 1.14 to 1.22, and HR 1.29, CI
1.26 to 1.33, respectively) and above and below age 65
years (HR 1.17, CI 1.13 to 1.20, and HR 1.44, CI 1.39 to
1.50, respectively). As a test of specificity, among users of
acid suppression therapy, PPI use was not associated with
increased risk of the tracer outcome of a motor vehicle
accident (HR 0.99, CI 0.89 to 1.10).
Discussion
This study provides insights into the excess risk of death
associated with PPI use. In a large primary cohort of new
users of acid suppression therapy followed for a median
of 5.71 years, we show a significant association between
PPI use and risk of all-cause mortality. Risk was increased
among those with no documented medical indications
for PPI use and with prolonged duration of use. The
results were consistent in multiple analyses and robust
to changes in epidemiological design and statistical specifications, and were reproduced in an earlier and less
contemporary cohort from an era where PPI use was far
less frequent.45
8

PPI are widely used by millions of people for indications
and durations that were never tested or approved; they
are available over the counter (without prescription) in
several countries and generally perceived as safe class of
therapeutics. They are often overprescribed, rarely deprescribed and frequently started inappropriately during a
hospital stay, and their use extended for long-term duration without appropriate medical indication.46–50 Results
of nationally representative data from the National
Health and Nutrition Examination Survey, where analyses were weighted to represent the US adult population,
showed that the use of prescription PPI increased from
3.9% to 7.8% from 1999–2000 to 2011–2012, representing a doubling of prevalence ratio.45 Studies estimate
that between 53% and 69% of PPI prescriptions are for
inappropriate indications46 51 where benefits of PPI use
may not justify the risks for many users.51–53 The findings
in our study highlight a potential excess risk of death
among users of PPI, and in particular among cohort
participants without GI comorbidities, and that risk is
increased with prolonged duration of PPI exposure.
Although our results should not deter prescription and
use of PPI where medically indicated, they may be used to
encourage and promote pharmacovigilance and emphasise the need to exercise judicious use of PPI and limit
use and duration of therapy to instances where there is

Figure 2 Duration of PPI exposure and risk of death among
new PPI users (n=166 098). PPI, proton pump inhibitor.
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a clear medical indication and where benefit outweighs
potential risk.1 Standardised guidelines for initiating
PPI prescription may lead to reduced overuse,54 regular
review of prescription and over-the-counter medications
and deprescription where a medical indication for PPI
treatment ceases to exist may be a meritorious approach.52
The biologic mechanism underpinning the association
of PPI use and risk of death is not clear. Experimental
evidence in rats suggests that PPI administration limits the
regenerative capacity of livers following partial hepatectomy.55 Administration of PPI upregulates expression of
mRNA and protein level and results in increased activity
of the heme oxygenase-1 enzyme in gastric and endothelial cells.56 Heme oxygenase-1 is generally seen as salutary,
but its beneficial properties are vitiated at higher doses,
and with sustained duration of expression.57 PPI treatment impairs lysosomal acidification and proteostasis
and results in increased oxidative stress, dysfunction, telomere shortening and accelerated senescence of human
endothelial cells.18 58 Wu and collaborators undertook
a systematic toxicity mechanism analysis using a highthroughput in silico analysis of microarray data; they
reported that PPI upregulated genes in the cellular
retinol metabolism pathway and downregulated genes
in the complement and coagulation cascades pathway,
and that PPI may block pathways of antigen presentation
and abrogate the synthesis and secretion of cytokines
and complement component proteins and coagulation
factors.58 59 How the changes in gene expression contribute
to excess risk of death is not yet entirely clear. The plausible clinical course leading to heightened risk of death is
likely mediated by the occurrence of one or more of the
adverse events associated with PPI use (kidney disease,
dementia, hypomagnesemia, C. difficile infection, osteoporotic fracture and so on). Further studies are needed to
characterise the biologic mechanisms that might explain
the epidemiological findings in this report.
The constellation of findings in this report must be
interpreted with the full cognizance of the observational
study design where confounding by indication and selection bias may represent limitations. We employed an
analytic strategy to evaluate the risk of death among users
of acid suppression therapy (PPI and H2 blockers), a class
of therapeutics generally prescribed for similar indications, a strategy that may lessen but does not completely
eliminate the possibility of confounding by indication
bias. We additionally built time-dependent propensity
score-matched cohort and high-dimensional propensity score-adjusted models, and we employed the use of
instrumental variable to reduce potential confounding
bias. Although we accounted for known covariates in our
analyses, it is possible that there are residual confounders
(either unmeasured or unknown) that may still confound
the association of PPI and risk of death. However, we
evaluated the impact of residual confounding in quantitative bias analyses, and the results suggest that even
with the application of unlikely (and exaggerated) set
of assumptions, the risk cannot be fully explained by
Xie Y, et al. BMJ Open 2017;7:e015735. doi:10.1136/bmjopen-2016-015735

residual confounding. In our analyses, we defined drug
exposure as having a prescription for it. Because PPIs
(and H2 blockers) are available over the counter in
the USA, it is possible that some patients in this cohort
may have obtained and used PPI without prescription.
However, owing to financial considerations, this is not
highly likely, and if it occurred in some patients, it will
have biased the results against the primary hypothesis and
resulted in underestimation of risk. The cohort included
mostly older white male US veterans, which may limit the
generalisability of study results to a broader population.
Our data sets did not include information on the cause
of death. The study has a number of strengths, including
the use of national large-scale data from a network of
integrated health systems, which were captured during
routine medical care that minimises selection bias. We
employed a new user (incident user) approach and evaluated the association between PPI use and risk of death
using a number of analytical approaches where we consistently found a significant association between PPI use and
increased risk of death. The consistency of study findings
in our report and the growing body of evidence in the
literature showing a host of adverse events associated with
PPI use are compelling, and because of the high prevalence of PPI use, it may have public health implications.
Exercising pharmacovigilance and limiting PPI use to
instances and durations where it is medically indicated
may be warranted.
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